Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)

NCT07612215 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07612215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)
Lead sponsor
NYU Langone Health
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 13, 2026
Completion date
May 31, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er positive, her2 positive breast cancer